Given that increased levels of Bcl‐2 proteins have been reported in different cancer types correlating with chemotherapy resistance and poor prognosis [Miyashita & Reed, 1993], Bcl‐2 proteins have become a viable target for anticancer therapy. The gene discussed is BCL2; the disease is cancer.